drugset / Trial / NCT00879216

VA106483 and Alpha Blocker Interaction Study in Elderly Males

NCT00879216 ↗

Phase 1 Completed 12 enrolled Vantia Ltd
RandomizedCrossoverTriple-blindTreatment

Summary

The main purpose of this study is to investigate whether the hypotensive effects of an alpha-blocker are increased when VA106483 is given at the same time.

Timeline

Start
2009-04
Primary completion
2009-05
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject VA106483 Small molecule 4 mg Oral

Indications